Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42
Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C
- Combination of linagliptin and metformin significantly reduced blood glucose levels compared with linagliptin alone
Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint
Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening
THOUSAND OAKS, Calif. and
Allergan Files Lawsuit in Federal Court against Valeant and Pershing Square for Violations of Federal Securities Laws
Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening Results to Form Basis of Regulatory Filings Beginning in 1H 2015
Third product from the BI-Lilly Diabetes alliance to be approved by FDA
RIDGEFIELD, Conn., and INDIANAPO
European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL
Managed Health Care Stocks Technical Review -- WellCare Health Plans, Aetna, Centene, WellPoint, and Molina Healthcare
Editor Note: For more information about this release, please scroll to bottom.
LONDON, July 30, 2014
PISCATAWAY, N.J., July 30, 2014 /PRNewswire/ -- InnoPharma, Inc.